Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Behavioral Neuroscience Reports
Erschienen in:

01.06.2019 | Psychosis (A Ahmed, Section Editor)

Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia

verfasst von: Maju Mathew Koola, Samir Kumar Praharaj, Anilkumar Pillai

Erschienen in: Current Behavioral Neuroscience Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The objective of this article is to highlight the potential role of the galantamine-memantine combination as a novel antioxidant treatment for schizophrenia.

Recent Findings

In addition to the well-known mechanisms of action of galantamine and memantine, these medications also have antioxidant activity. Furthermore, an interplay exists between oxidative stress, inflammation (redox-inflammatory hypothesis), and kynurenine pathway metabolites. Also, there is an interaction between brain-derived neurotrophic factor and oxidative stress in schizophrenia. Oxidative stress may be associated with positive, cognitive, and negative symptoms and impairments in white matter integrity in schizophrenia. The antipsychotic-galantamine-memantine combination may provide a novel strategy in schizophrenia to treat positive, cognitive, and negative symptoms.

Summary

A “single antioxidant” may be inadequate to counteract the complex cascade of oxidative stress. The galantamine-memantine combination as “double antioxidants” is promising. Hence, randomized controlled trials are warranted with the antipsychotic-galantamine-memantine combination with oxidative stress and antioxidant biomarkers in schizophrenia.
Literatur
1.
• Hoskins RG. Oxygen metabolism in schizophrenia. Arch Neurol Psychiatr. 1937;38(6):1261–70 This is presumably the first publication on oxygen metabolism in schizophrenia. CrossRef
2.
• Hoffer A, Osmond H, Smythies J. Schizophrenia; a new approach. II. Result of a year’s research. J Ment Sci. 1954;100(418):29–45 This is one of the first publications on oxidative stress in schizophrenia. CrossRefPubMed
3.
Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1–2):45–54.CrossRefPubMed
4.
Ramchand CN, Davies JI, Tresman RL, Griffiths IC, Peet M. Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1–2):27–31.CrossRefPubMed
5.
Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1–2):33–43.CrossRefPubMed
6.
Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:200–6.CrossRef
7.
• Möller M, Swanepoel T, Harvey BH. Neurodevelopmental animal models reveal the convergent role of neurotransmitter systems, inflammation, and oxidative stress as biomarkers of schizophrenia: implications for novel drug development. ACS Chem Neurosci. 2015;6(7):987–1016 This article illustrated the interplay between inflammation, oxidative stress, and the kynurenine pathway and discussed the role of memantine as an antioxidant. CrossRefPubMed
8.
Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale. 2006;32(2 Pt 1):244–52.CrossRefPubMed
9.
Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci. 2006;60(4):458–64.CrossRefPubMed
10.
Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19(2):220–30.CrossRefPubMed
11.
12.
13.
Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15(7):2003–10.CrossRefPubMed
14.
Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal. 2011;15(7):2067–79.CrossRefPubMed
15.
• Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15(7):2011–35 This is a comprehensive review on oxidative stress in schizophrenia. CrossRefPubMedPubMedCentral
16.
Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014;9(7):e101652.CrossRefPubMedPubMedCentral
17.
Sertan Copoglu U, Virit O, Hanifi Kokacya M, Orkmez M, Bulbul F, Binnur Erbagci A, et al. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res. 2015;229(1–2):200–5.CrossRefPubMed
18.
Shim S, Shuman M, Duncan E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophr Res. 2016;170(1):226–31.CrossRefPubMed
19.
Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. 2017;188:98–109.CrossRefPubMed
20.
Boll KM, Noto C, Bonifácio KL, Bortolasci CC, Gadelha A, Bressan RA, et al. Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Res. 2017;253:43–8.CrossRefPubMed
21.
• Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010;53(1):112–24 This is a meta-analysis of studies on oxidative stress in schizophrenia. CrossRefPubMed
22.
• Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400–9 This is a meta-analysis of 44 studies of oxidative stress in schizophrenia. CrossRefPubMedPubMedCentral
23.
•• Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, et al. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr Res. 2014;157(1–3):84–9 This article was the first to shed light on the potential role of the galantamine-memantine combination in schizophrenia and described how the combination may counteract the effects of kynurenic acid. CrossRefPubMedPubMedCentral
24.
Koola MM. Kynurenine pathway and cognitive impairments in schizophrenia: pharmacogenetics of galantamine and memantine. SchizophrRes Cogn. 2016;4:4–9.CrossRef
25.
•• Koola MM. Potential role of antipsychotic-galantamine-memantine combination for the treatment of positive, cognitive and negative symptoms of schizophrenia. Mol Neuropsychiatry. 2018;4:134–48 This article reviewed how the antipsychotic-galantamine-memantine combination may improve positive, cognitive, and negative symptoms concurrently. CrossRefPubMed
26.
Noto C, Ota VK, Gadelha A, Noto MN, Barbosa DS, Bonifácio KL, et al. Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res. 2015;68:210–6.CrossRefPubMed
27.
Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15(4):316–28.CrossRefPubMed
28.
Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, et al. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell. 2008;7(4):506–15.CrossRefPubMedPubMedCentral
29.
• Golse B, Debray Q, Puget K, Michelson AM. Superoxide dismutase 1 and glutathione peroxidase levels in erythrocytes of adult schizophrenics. Nouv Press Med. 1978;7(23):2070–1 This is one of the earliest articles showing oxidative stress biomarkers in schizophrenia.
30.
Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B. 2006;7(12):981–6.CrossRefPubMedPubMedCentral
31.
Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12(10):3721–8.CrossRefPubMed
32.
Leipnitz G, Schumacher C, Scussiato K, Dalcin KB, Wannmacher CM, Wyse AT, et al. Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats. Int J Dev Neurosci. 2005;23(8):695–701.CrossRefPubMed
33.
Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):995–1005.CrossRefPubMed
34.
Dietrich-Muszalska A, Olas B, Głowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology. 2009;59(1):1–7.CrossRefPubMed
35.
Kano S, Colantuoni C, Han F, Zhou Z, Yuan Q, Wilson A, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18(7):740–2.CrossRefPubMed
36.
•• Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:214–23 This comprehensive review showed all the oxidative stress and antioxidant biomarkers in schizophrenia that have been validated. CrossRef
37.
Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One. 2008;3(4):e1944.CrossRefPubMedPubMedCentral
38.
Albayrak Y, Ünsal C, Beyazyüz M, Ünal A, Kuloğlu M. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:144–9.CrossRef
39.
Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry. 2015;20(7):827–38.CrossRefPubMed
40.
Alameda L, Fournier M, Khadimallah I, Griffa A, Cleusix M, Jenni R, et al. Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis. Proc Natl Acad Sci U S A. 2018;115(49):12495–500.CrossRefPubMedPubMedCentral
41.
Chittiprol S, Venkatasubramanian G, Neelakantachar N, Babu SV, Reddy NA, Shetty KT, et al. Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res. 2010;44:310–3.CrossRefPubMed
42.
Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem. 1998;71(3):1002–12.CrossRefPubMed
43.
Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett. 2004;372(1–2):157–60.CrossRefPubMed
44.
Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol. 1995;49(3):359–65.CrossRefPubMed
45.
Pillai A, Parikh V, Terry AV Jr, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res. 2007;41(5):372–86.CrossRefPubMed
46.
Kriisa K, Haring L, Vasar E, Koido K, Janno S, Vasar V, et al. Antipsychotic treatment reduces indices of oxidative stress in first-episode psychosis patients. Oxidative Med Cell Longev. 2016;2016:9616593.CrossRef
47.
Hill VM, O'Connor RM, Sissoko GB, Irobunda IS, Leong S, Canman JC, et al. A bidirectional relationship between sleep and oxidative stress in Drosophila. PLoS Biol. 2018;16(7):e2005206.CrossRefPubMedPubMedCentral
48.
•• Traykova M, Traykov T, Hadjimitova V, Krikorian K, Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Z Naturforsch C. 2003;58(5–6):361–5 This article highlighted the antioxidant properties of galantamine. CrossRefPubMed
49.
•• Ezoulin MJ, Ombetta JE, Dutertre-Catella H, Warnet JM, Massicot F. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology. 2008;29(2):270–7 This article sheds light on the antioxidant properties of galantamine. CrossRefPubMed
50.
•• Melo JB, Sousa C, Garção P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci. 2009;29(3):455–64 This study showed the antioxidant activity of galantamine. CrossRefPubMed
51.
•• Triana-Vidal LE, Carvajal-Varona SM. Protective effect of galantamine against oxidative damage using human lymphocytes: a novel in vitro model. Arch Med Res. 2013;44(2):85–92 This article described galantamine’s antioxidant properties. CrossRefPubMed
52.
•• Tsvetkova D, Obreshkova D, Zheleva-Dimitrova D, Saso L. Antioxidant activity of galantamine and some of its derivatives. Curr Med Chem. 2013;20(36):4595–608 This article illustrated the antioxidant properties of galantamine. CrossRefPubMed
53.
Tanović A, Alfaro V. Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular dementia. Rev Neurol. 2006;42(10):607–16.PubMed
54.
De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282(15):11590–601.CrossRefPubMed
55.
•• Pietá Dias C, Martins de Lima MN, Presti-Torres J, Dornelles A, Garcia VA, Siciliani Scalco F, et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience. 2007;146(4):1719–25 This study demonstrated that memantine enhanced cognition by reducing oxidative stress. CrossRefPubMed
56.
Liu W, Xu Z, Deng Y, Xu B, Wei Y, Yang T. Protective effects of memantine against methylmercury-induced glutamate dyshomeostasis and oxidative stress in rat cerebral cortex. Neurotox Res. 2013;24(3):320–37.CrossRefPubMed
57.
•• Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, Di Filippo ES, et al. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer’s disease. Eur J Pharm Sci. 2013;49(2):187–98 This article demonstrated the antioxidant role of memantine. CrossRefPubMed
58.
Rajasekar N, Nath C, Hanif K, Shukla R. Inhibitory effect of memantine on streptozotocin-induced insulin receptor dysfunction, neuroinflammation, amyloidogenesis, and neurotrophic factor decline in astrocytes. Mol Neurobiol. 2016;53(10):6730–44.CrossRefPubMed
59.
Lewerenz J, Letz J, Methner A. Activation of stimulatory heterotrimeric G proteins increases glutathione and protects neuronal cells against oxidative stress. J Neurochem. 2003;87(2):522–31.CrossRefPubMed
60.
Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets. 2010;9(3):373–82.CrossRefPubMed
61.
Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (−) : cystine supplier and beyond. Amino Acids. 2012;42(1):231–46.CrossRefPubMed
62.
Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(−) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522–55.CrossRefPubMedPubMedCentral
63.
Liu X, Albano R, Lobner D. FGF-2 induces neuronal death through upregulation of system xc. Brain Res. 2014;1547:25–33.CrossRefPubMed
64.
Kong L, Albano R, Madayag A, Raddatz N, Mantsch JR, Choi S, et al. Pituitary adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc. J Neurochem. 2016;137(3):384–93.CrossRefPubMedPubMedCentral
65.
Lewerenz J, Klein M, Methner A. Cooperative action of glutamate transporters and cystine/glutamate antiporter system xc- protects from oxidative glutamate toxicity. J Neurochem. 2006;98(3):916–25.CrossRefPubMed
66.
•• Okada M, Fukuyama K, Kawano Y, Shiroyama T, Ueda Y. Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc. Pharmacol Res Perspect. 2019;7(1):e00457 This is the first article to show that memantine (in addition to action on the NMDA receptors) has action via activation of system xc (glutamate/cystine-antiporter). CrossRefPubMedPubMedCentral
67.
•• Lorrio S, Negredo P, Roda JM, García AG, López MG. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res. 2009;1254:128–37 This study demonstrated that the combination of galantamine and memantine had synergistic effect on the antioxidant biomarker; a finding that was not seen with either medication alone. CrossRefPubMed
68.
Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, et al. Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol Dial Transplant. 2014;29(3):529–38.CrossRefPubMed
69.
Praticò D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharmacol Sci. 2008;29(12):609–15.CrossRefPubMed
70.
Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, et al. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem. 2018;33(1):583–606.CrossRefPubMedPubMedCentral
71.
•• Koola MM, Nikiforuk A, Pillai A, Parsaik AK. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Journal of Geriatric Care and Research. 2018;5(2):57–67 This comprehensive review illustrated how the galantamine-memantine combination may have synergistic action on oxidative stress. PubMedPubMedCentral
72.
Sawa A, Sedlak TW. Oxidative stress and inflammation in schizophrenia. Schizophr Res. 2016;176(1):1–2.CrossRefPubMed
73.
Müller N, Myint AM, Schwarz MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des. 2011;17(2):130–6.CrossRefPubMed
74.
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465–77.CrossRefPubMedPubMedCentral
75.
Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, et al. Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid. Mol Neurobiol. 2018;55(2):1524–36.CrossRefPubMed
76.
•• Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, Carrillo-Mora P, Pedraza-Chaverrí J, Silva-Adaya D, et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 2011;33(5):538–47 This article discussed the antioxidant activity of kynurenic acid. CrossRefPubMed
77.
Christen S, Peterhans E, Stocker R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc Natl Acad Sci U S A. 1990;87(7):2506–10.CrossRefPubMedPubMedCentral
78.
Goldstein LE, Leopold MC, Huang X, Atwood CS, Saunders AJ, Hartshorn M, et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000;39(24):7266–75.CrossRefPubMed
79.
Giles GI, Collins CA, Stone TW, Jacob C. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem Biophys Res Commun. 2003;300(3):719–24.CrossRefPubMed
80.
Leipnitz G, Schumacher C, Dalcin KB, Scussiato K, Solano A, Funchal C, et al. In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem Int. 2007;50(1):83–94.CrossRefPubMed
81.
Sas K, Robotka H, Toldi J, Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci. 2007;257(1–2):221–39.CrossRefPubMed
82.
Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington’s disease. CNS Neurol Disord Drug Targets. 2010;9(6):791–800.CrossRefPubMed
83.
Pérez-De La Cruz V, Carrillo-Mora P, Santamaría A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res. 2012;5:1–8.PubMed
84.
85.
Blanco Ayala T, Lugo Huitrón R, Carmona Aparicio L, Ramírez Ortega D, González Esquivel D, Pedraza Chaverrí J, et al. Alternative kynurenic acid synthesis routes studied in the rat cerebellum. Front Cell Neurosci. 2015;9:178.CrossRefPubMedPubMedCentral
86.
Zhuravlev AV, Zakharov GA, Shchegolev BF, Savvateeva-Popova EV. Antioxidant properties of kynurenines: density functional theory calculations. PLoS Comput Biol. 2016;12(11):e1005213.CrossRefPubMedPubMedCentral
87.
Réus GZ, Becker IRT, Scaini G, Petronilho F, Oses JP, Kaddurah-Daouk R, et al. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;81:55–63.CrossRef
88.
Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun. 2009;23(1):41–5.CrossRefPubMed
89.
Shifrin H, Nadler-Milbauer M, Shoham S, Weinstock M. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8(2):e57668.CrossRefPubMedPubMedCentral
90.
Wazea SA, Wadie W, Bahgat AK, El-Abhar HS. Galantamine anti-colitic effect: role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways. Sci Rep. 2018;8(1):5110.CrossRefPubMedPubMedCentral
91.
Gallowitsch-Puerta M, Tracey KJ. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann N Y Acad Sci. 2005;1062:209–19.CrossRefPubMed
92.
Liu Y, Zhang Y, Zheng X, Fang T, Yang X, Luo X, et al. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflammation. 2018;15(1):112.CrossRefPubMedPubMedCentral
93.
Wang T, Zhu H, Hou Y, Gu W, Wu H, Luan Y, et al. Galantamine reversed early postoperative cognitive deficit via alleviating inflammation and enhancing synaptic transmission in mouse hippocampus. Eur J Pharmacol. 2019;846:63–72.CrossRefPubMed
94.
Wang Z, He X, Fan X. Postnatal administration of memantine rescues TNF-α-induced decreased hippocampal precursor proliferation. Neurosci Lett. 2018;662:173–80.CrossRefPubMed
95.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. J Clin Psychopharmacol. 2014;34(3):337–43.CrossRefPubMed
96.
Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16(2–3):183–93.CrossRefPubMed
97.
Pandya CD, Kutiyanawalla A, Pillai A. BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J Psychiatr. 2013;6(1):22–8.CrossRefPubMed
98.
Golime R, Palit M, Acharya J, Dubey DK. Neuroprotective effects of galantamine on nerve agent-induced neuroglial and biochemical changes. Neurotox Res. 2018;33(4):738–48.CrossRefPubMed
99.
Amin SN, El-Aidi AA, Ali MM, Attia YM, Rashed LA. Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress: implications for memory and behavior. NeuroMolecular Med. 2015;17(2):121–36.CrossRefPubMed
100.
Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel. 2006;9(5):580–6.PubMed
101.
Pillai A, Mahadik SP. Increased truncated TrkB receptor expression and decreased BDNF/TrkB signaling in the frontal cortex of reeler mouse model of schizophrenia. Schizophr Res. 2008;100(1–3):325–33.CrossRefPubMed
102.
Autio H, Mätlik K, Rantamäki T, Lindemann L, Hoener MC, Chao M, et al. Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology. 2011;61(8):1291–6.CrossRefPubMedPubMedCentral
103.
Zhu G, Li J, He L, Wang X, Hong X. MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Br J Pharmacol. 2015;172(9):2354–68.CrossRefPubMedPubMedCentral
104.
Amidfar M, Kim YK, Wiborg O. Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress. Pharmacol Rep. 2018;70(3):600–6.CrossRefPubMed
105.
Khalil OS, Forrest CM, Pisar M, Smith RA, Darlington LG, Stone TW. Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation. Immunopharmacol Immunotoxicol. 2013;35(5):581–93.CrossRefPubMed
106.
Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun. 2013;28:170–81.CrossRefPubMed
107.
Zhang XY, Chen DC, Tan YL, Tan SP, Wang ZR, Yang FD, et al. The interplay between BDNF and oxidative stress in chronic schizophrenia. Psychoneuroendocrinology. 2015;51:201–8.CrossRefPubMed
108.
Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, McGeer PL. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010;24(7):2533–45.CrossRefPubMed
109.
Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40(2):126–33.PubMedPubMedCentral
110.
Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009;23(2):91–101.CrossRefPubMed
111.
Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010;36:211–8.CrossRefPubMedPubMedCentral
112.
Koola MM, Sklar J, Davis W, Nikiforuk A, Meissen JK, Sawant-Basak A, et al. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. Schizophr Res. 2018;193:459–60.CrossRefPubMed
113.
Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. In press.
114.
Mikkelsen JD, Thomsen MS, Hansen HH, Lichota J. Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discov Today. 2010;15(3–4):137–41.CrossRefPubMed
115.
Koola MM. Galantamine-memantine combination for cognitive impairments due to electroconvulsive therapy, traumatic brain injury, and neurologic and psychiatric disorders: kynurenic acid and mismatch negativity target engagement. Prim Care Companion CNS Disord. 2018;20(2). https://​doi.​org/​10.​4088/​PCC.​17nr02235.
116.
•• Koola MM. Attenuated mismatch negativity in attenuated psychosis syndrome predicts psychosis: can galantamine-memantine combination prevent psychosis? Mol Neuropsychiatry. 2018;4:71–4 This article discussed how enhancing mismatch negativity may prevent schizophrenia. The combination has an additional advantage of having antioxidant activity. CrossRefPubMed
117.
Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol. 2001;86(6):3043–55.CrossRefPubMed
118.
Buhler AV, Dunwiddie TV. alpha7 nicotinic acetylcholine receptors on GABAergic interneurons evoke dendritic and somatic inhibition of hippocampal neurons. J Neurophysiol. 2002;87(1):548–57.CrossRefPubMed
119.
Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63(10):1372–6.CrossRefPubMed
120.
Balla A, Nattini ME, Sershen H, Lajtha A, Dunlop DS, Javitt DC. GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology. 2009;56(5):915–21.CrossRefPubMedPubMedCentral
121.
Beggiato S, Tanganelli S, Fuxe K, Antonelli T, Schwarcz R, Ferraro L. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex. Neuropharmacology. 2014;82:11–8.CrossRefPubMed
122.
Townsend M, Whyment A, Walczak JS, Jeggo R, van den Top M, Flood DG, et al. α7-nAChR agonist enhances neural plasticity in the hippocampus via a GABAergic circuit. J Neurophysiol. 2016;116(6):2663–75.CrossRefPubMedPubMedCentral
123.
Flores-Barrera E, Thomases DR, Cass DK, Bhandari A, Schwarcz R, Bruno JP, et al. Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the α7nACh negative modulator kynurenic acid. J Neurosci. 2017;37(33):7921–9.CrossRefPubMedPubMedCentral
124.
Bali ZK, Nagy LV, Hernádi I. Alpha7 nicotinic acetylcholine receptors play a predominant role in the cholinergic potentiation of N-methyl-D-aspartate evoked firing responses of hippocampal CA1 pyramidal cells. Front Cell Neurosci. 2017;11:271.CrossRefPubMedPubMedCentral
125.
Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophr Res. 2016;176(1):41–51.CrossRefPubMed
126.
•• Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol. 2017;152:3–20 This article argues for a paradigm shift in the pharmacological treatment of schizophrenia. CrossRefPubMed
127.
Koola MM, Parsaik AK. Galantamine-memantine combination effective in dementia: translate to dementia praecox? Schizophr Res Cogn. 2018;12:8–10.CrossRefPubMedPubMedCentral
128.
Koola MM. Galantamine and memantine combination for cognition: enough or more than enough to translate from murines and macaques to men with schizophrenia? Asian J Psychiatr. In press.
129.
Aramakis VB, Metherate R. Nicotine selectively enhances NMDA receptor-mediated synaptic transmission during postnatal development in sensory neocortex. J Neurosci. 1998;18(20):8485–95.CrossRefPubMed
130.
Neumeister KL, Riepe MW. Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2012;30(2):245–51.CrossRefPubMed
131.
Nikiforuk A, Potasiewicz A, Kos T, Popik P. The combination of memantine and galantamine improves cognition in rats: the synergistic role of the α7 nicotinic acetylcholine and NMDA receptors. Behav Brain Res. 2016;313:214–8.CrossRefPubMed
132.
Gmiro VE, Serdiuk SE. The search for selective blockers of NMDA and AMPA/kainate receptors in a series of bis-ammonium compounds with adamantyl radicals. Eksp Klin Farmakol. 2000;63(1):7–13.PubMed
133.
Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J Clin Pharmacol. 2006;46(7 Suppl 1):8S–16S.CrossRefPubMed
134.
Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, et al. Cognitive enhancer effects of low Memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front Pharmacol. 2019;10:73.CrossRefPubMedPubMedCentral
135.
Knott V, Shah D, Millar A, McIntosh J, Fisher D, Blais C, et al. Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait. Front Pharmacol. 2012;3:172.CrossRefPubMedPubMedCentral
136.
Hamilton HK, D'Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, et al. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: implications for schizophrenia. Schizophr Res. 2018;191:87–94.CrossRefPubMed
137.
Beggiato S, Antonelli T, Tomasini MC, Tanganelli S, Fuxe K, Schwarcz R, et al. Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur J Neurosci. 2013;37(9):1470–7.CrossRefPubMed
138.
Dashniani MG, Burdzhanadze MA, Naneĭshvili TL, Kruashvili LB, Sephashvili MM. Effects of chronic memantine treatment on hippocampal extracellular glutamate and GABA levels during spatial alternation testing. Georgian Med News. 2012;202:68–75.
139.
Ahnaou A, Huysmans H, Jacobs T, Drinkenburg WH. Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential. Neuropharmacology. 2014;86:362–77.CrossRefPubMed
140.
Ma J, Mufti A, Stan Leung L. Effects of memantine on hippocampal long-term potentiation, gamma activity, and sensorimotor gating in freely moving rats. Neurobiol Aging. 2015;36(9):2544–54.CrossRefPubMed
141.
Gascoyne LE, Mullinger KJ, Robson SE, Kumar J, O'Neill GC, Palaniyappan L, et al. Changes in electrophysiological markers of cognitive control after administration of galantamine. Neuroimage Clin. 2018;20:228–35.CrossRefPubMedPubMedCentral
142.
Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia. Neuropsychopharmacology. 2017;42(13):2633–9.CrossRefPubMedPubMedCentral
143.
Shao S, Li M, Du W, Shao F, Wang W. Galantamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment. Brain Res. 2014;1589:105–11.CrossRefPubMed
144.
Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacology. 2016;41(2):419–30.CrossRefPubMed
145.
Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull. 2004;64(2):165–70.CrossRefPubMed
146.
Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 2009;34(10):2344–57.CrossRefPubMedPubMedCentral
147.
Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ramírez MJ, Cedazo-Mínguez A. Cholinergic hypofunction impairs memory acquisition possibly through hippocampal arc and BDNF downregulation. Hippocampus. 2011;21(9):999–1009.PubMed
148.
Marvanová M, Lakso M, Pirhonen J, Nawa H, Wong G, Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci. 2001;18(3):247–58.CrossRefPubMed
149.
Massey KA, Zago WM, Berg DK. BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons. Mol Cell Neurosci. 2006;33(4):381–8.CrossRefPubMedPubMedCentral
150.
Navakkode S, Korte M. Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage. Hippocampus. 2012;22(2):335–46.CrossRefPubMed
151.
Penadés R, García-Rizo C, Bioque M, González-Rodríguez A, Cabrera B, Mezquida G, et al. The search for new biomarkers for cognition in schizophrenia. Schizophr Res Cogn. 2015;2(4):172–8.CrossRefPubMedPubMedCentral
152.
Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Edden RA, et al. Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study. Transl Psychiatry. 2016;6(11):e967.CrossRefPubMedPubMedCentral
153.
Sobrado M, Roda JM, López MG, Egea J, García AG. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett. 2004;365(2):132–6.CrossRefPubMed
154.
Hodgkins PS, Schwarcz R. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur J Neurosci. 1998;10(6):1986–94.CrossRefPubMed
155.
Chen Y, Brew BJ, Guillemin GJ. Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem. 2011;118(5):816–25.CrossRefPubMed
156.
Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry. 2009;65(6):489–94.CrossRefPubMed
157.
Sullivan CR, Mielnik CA, Funk A, O'Donovan SM, Bentea E, Pletnikov M, et al. Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophrenia. Sci Rep. 2019; 9(1):5087
158.
Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9(7):684–97, 643.CrossRefPubMed
159.
160.
161.
Singh N, Hroudová J, Fišar Z. In vitro effects of cognitives and nootropics on mitochondrial respiration and monoamine oxidase activity. Mol Neurobiol. 2017;54(8):5894–904.CrossRefPubMed
162.
Lee NY, Choi HO, Kang YS. The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier. Neurochem Res. 2012;37(7):1499–507.CrossRefPubMed
163.
Paul C, Bolton C. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. J Pharmacol Exp Ther. 2002;302(1):50–7.CrossRefPubMed
164.
Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. 2004;46(1):103–14.CrossRefPubMed
165.
Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β1-40. Eur J Pharmacol. 2012;692(1–3):38–45.CrossRefPubMed
166.
Noda Y, Mouri A, Ando Y, Waki Y, Yamada SN, Yoshimi A, et al. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharmacol. 2010;13(10):1343–54.CrossRefPubMed
167.
Almeida RC, Souza DG, Soletti RC, López MG, Rodrigues AL, Gabilan NH. Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice. Neurosci Lett. 2006;395(2):93–7.CrossRefPubMed
168.
Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. J Pharmacol Exp Ther. 2006;317(1):30–6.CrossRefPubMed
169.
Unger C, Svedberg MM, Schutte M, Bednar I, Nordberg A. Effect of memantine on the alpha 7 neuronal nicotinic receptors, synaptophysin- and low molecular weight MAP-2 levels in the brain of transgenic mice over-expressing human acetylcholinesterase. J Neural Transm (Vienna). 2005;112(2):255–68.CrossRef
170.
Osimo EF, Beck K, Reis Marques T, Howes OD. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry. 2019 Apr;24(4):549–61.
171.
Koola MM, Pillai A, Looney SW. Targeting nicotinic and NMDA receptors concurrently: Rocket science, common sense or game changer? Schizophr. Bull. 2019 Apr;45(2):S248-S248·
172.
Spedding M. New directions for drug discovery. Dialogues Clin Neurosci. 2006;8(3):295-301
173.
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008;31(5):234–42.CrossRefPubMedPubMedCentral
174.
Díez Á, Suazo V, Casado P, Martín-Loeches M, Molina V. Gamma power and cognition in patients with schizophrenia and their first-degree relatives. Neuropsychobiology. 2014;69(2):120–8.CrossRefPubMed
175.
Sun C, Zhou P, Wang C, Fan Y, Tian Q, Dong F, et al. Defects of gamma oscillations in auditory steady-state evoked potential of schizophrenia. Shanghai Arch Psychiatry. 2018;30(1):27–38.PubMed
176.
Zhou TH, Mueller NE, Spencer KM, Mallya SG, Lewandowski KE, Norris LA, et al. Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder. Schizophr Res. 2018;201:278–86.CrossRefPubMed
177.
Leicht G, Vauth S, Polomac N, Andreou C, Rauh J, Mußmann M, et al. EEG-informed fMRI reveals a disturbed gamma-band-specific network in subjects at high risk for psychosis. Schizophr Bull. 2016;42(1):239–49.PubMed
178.
Gandal MJ, Edgar JC, Klook K, Siegel SJ. Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology. 2012;62(3):1504–18.CrossRefPubMed
179.
Uhlhaas PJ, Singer W. High-frequency oscillations and the neurobiology of schizophrenia. Dialogues Clin Neurosci. 2013;15(3):301–13.PubMedPubMedCentral
180.
O'Donnell BF, Vohs JL, Krishnan GP, Rass O, Hetrick WP, Morzorati SL. The auditory steady-state response (ASSR): a translational biomarker for schizophrenia. Suppl Clin Neurophysiol. 2013;62:101–12.CrossRefPubMedPubMedCentral
181.
Phillips KG, Uhlhaas PJ. Neural oscillations as a translational tool in schizophrenia research: rationale, paradigms and challenges. J Psychopharmacol. 2015;29(2):155–68.CrossRefPubMed
182.
Tada M, Nagai T, Kirihara K, Koike S, Suga M, Araki T, et al. Differential alterations of auditory gamma oscillatory responses between pre-onset high-risk individuals and first-episode schizophrenia. Cereb Cortex. 2016;26(3):1027–35.CrossRefPubMed
183.
Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyi P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature. 1995;378(6552):75–8.CrossRefPubMed
184.
Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698–702.CrossRefPubMedPubMedCentral
185.
Whittington MA, Traub RD, Jefferys JG. Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature. 1995;373(6515):612–5.CrossRefPubMed
186.
Carlén M, Meletis K, Siegle JH, Cardin JA, Futai K, Vierling-Claassen D, et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry. 2012;17(5):537–48.CrossRefPubMed
187.
Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull. 2012;38(5):950–7.CrossRefPubMedPubMedCentral
188.
Sullivan EM, Timi P, Hong LE, O'Donnell P. Effects of NMDA and GABA-A receptor antagonism on auditory steady-state synchronization in awake behaving rats. Int J Neuropsychopharmacol. 2015;18(7):pyu118.CrossRefPubMedPubMedCentral
189.
Stoiljkovic M, Kelley C, Nagy D, Leventhal L, Hajós M. Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations. Neuropharmacology. 2016;110:102–8.CrossRefPubMed
190.
Zhang X, Ge XY, Wang JG, Wang YL, Wang Y, Yu Y, et al. Induction of long-term oscillations in the γ frequency band by nAChR activation in rat hippocampal CA3 area. Neuroscience. 2015;301:49–60.CrossRefPubMed
191.
Hasam-Henderson LA, Gotti GC, Mishto M, Klisch C, Gerevich Z, Geiger JRP, et al. NMDA-receptor inhibition and oxidative stress during hippocampal maturation differentially alter parvalbumin expression and gamma-band activity. Sci Rep. 2018;8(1):9545.CrossRefPubMedPubMedCentral
192.
Ballesteros A, Summerfelt A, Du X, Jiang P, Chiappelli J, Tagamets M, et al. Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol. 2013;124(11):2209–15.CrossRefPubMedPubMedCentral
193.
• Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, et al. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology. 2018;43(8):1700–5 This study showed that the redox system is abnormal in clinical high risk for psychosis. CrossRefPubMedPubMedCentral
194.
Lavoie S, Berger M, Schlögelhofer M, Schäfer MR, Rice S, Kim SW, et al. Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Transl Psychiatry. 2017;7(3):e1064.CrossRefPubMedPubMedCentral
195.
Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, et al. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 2014;41:23–32.CrossRefPubMed
196.
Zeni-Graiff M, Rizzo LB, Mansur RB, Maurya PK, Sethi S, Cunha GR, et al. Peripheral immuno-inflammatory abnormalities in ultra-high risk of developing psychosis. Schizophr Res. 2016;176(2–3):191–5.CrossRefPubMed
197.
Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015;2(5):403–12.CrossRefPubMed
198.
Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, et al. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull. 2015;41(2):419–28.CrossRefPubMed
199.
Koola MM. Can N-acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity? Schizophr Res. In press.
200.
Demro C, Rowland L, Wijtenburg SA, Waltz J, Gold J, Kline E, et al. Glutamatergic metabolites among adolescents at risk for psychosis. Psychiatry Res. 2017;257:179–85.CrossRefPubMed
201.
Egerton A, Fusar-Poli P, Stone JM. Glutamate and psychosis risk. Curr Pharm Des. 2012;18(4):466–78.CrossRefPubMed
202.
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetylcysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33(9):2187–99.CrossRefPubMed
203.
Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr Bull. 2018;44(2):317–27.CrossRefPubMed
204.
• Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry. 2013;70(8):793–802 This article showed that there is adequate time to intervene in patients at ultra high risk for psychosis because of the long prodromal phase. CrossRefPubMed
205.
Löffler W, Häfner H. Long prodromal phase in schizophrenia. By recognizing it, the prognosis of the patient can be significantly improved. MMW Fortschr Med. 2000;142(10):26–9.PubMed
206.
Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res. 2003;60(1):21–32.CrossRefPubMed
207.
Do KQ, Cuenod M, Hensch TK. Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophr Bull. 2015;41(4):835–46.CrossRefPubMedPubMedCentral
208.
Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal glutamate and γ-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry. 2016;73(2):166–74.CrossRefPubMedPubMedCentral
209.
Cabungcal JH, Counotte DS, Lewis E, Tejeda HA, Piantadosi P, Pollock C, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014;83(5):1073–84.CrossRefPubMedPubMedCentral
210.
•• Sawa A, Seidman LJ. Is prophylactic psychiatry around the corner? Combating adolescent oxidative stress for adult psychosis and schizophrenia. Neuron. 2014;83(5):991–3 This article argues the importance of antioxidant treatment in the prevention of schizophrenia. CrossRefPubMed
211.
Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res. 2016;176(1):52–71.CrossRefPubMed
212.
Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62(3):195–204.CrossRefPubMed
213.
Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Kirtas O. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci. 2005;59(6):652–6.CrossRefPubMed
214.
Zhang XY, Zhou DF, Cao LY, Wu GY. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology. 2006;188(1):12–7.CrossRefPubMed
215.
Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351–62.CrossRefPubMed
216.
Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162(2):388–90.CrossRefPubMed
217.
Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:CD008919.PubMed
218.
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–8.CrossRefPubMed
219.
Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry. 2005;66(2):213–9.CrossRefPubMed
220.
Dickerson FB, Stallings CR, Origoni AE, Sullens A, Khushalani S, Sandson N, et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr Res. 2009;109(1–3):66–9.CrossRefPubMed
221.
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158(12):2071–4.CrossRefPubMed
222.
Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12(2):206–20.CrossRefPubMed
223.
Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res. 2014;59:125–31.CrossRefPubMed
224.
Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015;35(4):374–81.PubMedPubMedCentral
225.
Deakin B, Suckling J, Barnes TRE, Byrne K, Chaudhry IB, Dazzan P, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5(11):885–94.CrossRefPubMedPubMedCentral
226.
Weiser M, Levi L, Burshtein S, Chiriță R, Cirjaliu D, Gonen I, et al. The effect of minocycline on symptoms in schizophrenia: results from a randomized controlled trial. Schizophr Res. in press.
227.
Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39(2):417–35.CrossRefPubMed
228.
Bumb JM, Enning F, Leweke FM. Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother. 2015;16(7):1049–67.CrossRefPubMed
229.
Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017;31(5):373–88.CrossRefPubMed
230.
•• Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res J Psychiatr Res. 2019;108:57–83 This is a comprehensive review of 250 randomized controlled trials with one add-on medication, highlighting that one add-on medication is inadequate to treat three domains of psychopathology. CrossRefPubMed
231.
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–27.CrossRefPubMed
232.
Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40(1):181–91.CrossRefPubMed
233.
Chen AT, Chibnall JT, Nasrallah HA. Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: a review. Ann Clin Psychiatry. 2016;28(3):190–6.PubMed
234.
Zheng W, Zhang QE, Cai DB, Yang XH, Qiu Y, Ungvari GS, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137(5):391–400.CrossRefPubMed
235.
Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017;22(5):415–26.CrossRefPubMed
236.
Xiang YQ, Zheng W, Wang SB, Yang XH, Cai DB, Ng CH, et al. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017;27(1):8–18.CrossRefPubMed
237.
Kelly DL, Wehring HJ. Minocycline as an evidence-based adjunct treatment in schizophrenia. Psychiatr Ann. 2018;48(5):224–31.CrossRef
238.
Abdel Baki SG, Schwab B, Haber M, Fenton AA, Bergold PJ. Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats. PLoS One. 2010;5(8):e12490.CrossRefPubMedPubMedCentral
239.
Haber M, Abdel Baki SG, Grin'kina NM, Irizarry R, Ershova A, Orsi S, et al. Minocycline plus N-acetylcysteine synergize to modulate inflammation and prevent cognitive and memory deficits in a rat model of mild traumatic brain injury. Exp Neurol. 2013;249:169–77.CrossRefPubMed
240.
Haber M, James J, Kim J, Sangobowale M, Irizarry R, Ho J, et al. Minocycline plus N-acteylcysteine induces remyelination, synergistically protects oligodendrocytes and modifies neuroinflammation in a rat model of mild traumatic brain injury. J Cereb Blood Flow Metab. 2018;38(8):1312–26.CrossRefPubMed
241.
Sangobowale M, Nikulina E, Bergold PJ. Minocycline plus N-acetylcysteine protect oligodendrocytes when first dosed 12 hours after closed head injury in mice. Neurosci Lett. 2018;682:16–20.CrossRefPubMed
242.
Sangobowale MA, Grin'kina NM, Whitney K, Nikulina E, St Laurent-Ariot K, Ho JS, et al. Minocycline plus N-acetylcysteine reduce behavioral deficits and improve histology with a clinically useful time window. J Neurotrauma. in press.
243.
Koola MM. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia. Asian J Psychiatr. 2019;40:100–2.CrossRefPubMed
244.
Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer’s disease. J Ethnopharmacol. 2018;215:42–73.CrossRefPubMed
245.
•• Sullivan EM, O'Donnell P. Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr Bull. 2012;38(3):373–6 This article argued that a combination treatment may be needed to target oxidative stress in schizophrenia and prodrome. CrossRefPubMedPubMedCentral
Metadaten
Titel
Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia
verfasst von
Maju Mathew Koola
Samir Kumar Praharaj
Anilkumar Pillai
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Current Behavioral Neuroscience Reports / Ausgabe 2/2019
Elektronische ISSN: 2196-2979
DOI
https://doi.org/10.1007/s40473-019-00174-5

Weitere Artikel der Ausgabe 2/2019

Frontal Alpha Asymmetry in Youth at Clinical High Risk for Psychosis

  • Psychosis (A Ahmed, Section Editor)

Remediation of Visual Processing Impairments in Schizophrenia: Where We Are and Where We Need to Be

  • Psychosis (A Ahmed, Section Editor)

Good Clinical Science Needs Rigorous Methodology, Enhanced Reproducibility, and Also Proper Citations

  • Neuromodulation (C Stagg, Section Editor)

Frustrative Non-reward and Lab-Based Paradigms for Advancing the Study of Aggression in Persons with Psychosis

  • Psychosis (A Ahmed, Section Editor)

Remote Monitoring for Understanding Mechanisms and Prediction in Psychiatry

  • Open Access
  • Mood and Anxiety Disorders (C Harmer, Section Editor)

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

CGRP-Antikörper auch bei älteren Migränekranken sicher

Beginnen ältere Migränekranke eine Prophylaxe mit CGRP-Antikörpern, kommt es anschließend nicht häufiger zu kardiovaskulären Problemen als unter einer Prophylaxe mit Botulinumtoxin. Darauf deutet eine US-Analyse von Medicare-Versicherten.

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Migräne verstehen und psychotherapeutisch behandeln

Das Wissen über die Mechanismen, die im Gehirn bei einer Migräneattacke ablaufen, und mögliche Auslöser wird immer breiter. Der psychologische Psychotherapeut Dr. Dipl.-Psych. Timo Klan fasst den aktuellen Erkenntnisstand zusammen. Und er gibt Tipps für eine differenzierte, individuelle Diagnostik auch von Begleiterkrankungen und beschreibt erfolgreiche psychotherapeutische Interventionen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise